FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Dexcel Pharma Technologies Ltd. 2. Issuer Name and Ticker or Trading Symbol Intec Pharma Ltd. [ NTEC ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)         (First)         (Middle)
1 DEXCEL STREET
3. Date of Earliest Transaction (MM/DD/YYYY)
1/31/2020
(Street)
OR AKIVA, L3 3060000
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares  1/31/2020    S    725951 (1) D(1) $0.309 (2)(5) 4424897  D   
Ordinary Shares  2/3/2020    S    80000 (1) D $0.318 (3)(5) 4344897  D   
Ordinary Shares  2/4/2020    S    110000 (1) D $0.290 (4)(5) 4234897  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  Dexcel Pharma Technologies Ltd ("DPT") and Dan Oren, DPT's Executive Chairman, are filing this Form 4 because they have beneficial ownership over ordinary shares of Intec Pharma Ltd. The Ordinary Shares are directly owned by DPT. Mr. Oren is ultimately the sole shareholder of DPT.
(2)  The price reported in Column 4 is the weighted average price. The Ordinary Shares were sold in multiple transactions at prices ranging from $0.300 to $0.325, inclusive.
(3)  The price reported in Column 4 is the weighted average price. The Ordinary Shares were sold in multiple transactions at prices ranging from $0.300 to $0.324, inclusive.
(4)  The price reported in Column 4 is the weighted average price. The Ordinary Shares were sold in multiple transactions at prices ranging from $0.290 to $0.294, inclusive.
(5)  The Reporting Persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Dexcel Pharma Technologies Ltd.
1 DEXCEL STREET
OR AKIVA, L3 3060000

X

Oren Dan
1 DEXCEL STREET
OR AKIVA, L3 3060000

X


Signatures
/s/ Dexcel Pharma Technologies Ltd. by Dan Oren, Executive Chairman 2/4/2020
**Signature of Reporting Person Date
/s/ Dan Oren 2/4/2020
**Signature of Reporting Person Date
Intec Pharma (NASDAQ:NTEC)
Historical Stock Chart
From Sep 2020 to Oct 2020 Click Here for more Intec Pharma Charts.
Intec Pharma (NASDAQ:NTEC)
Historical Stock Chart
From Oct 2019 to Oct 2020 Click Here for more Intec Pharma Charts.